Clinical studies are meant to evaluate and improve treatment and care of patients.
In an observational study, investigators (healthcare professionals) watch people diagnosed with a specific disease, such as multiple myeloma, and record various aspects of their health. People involved in observational studies do not get any treatment in addition to what they are already getting as part of their everyday care.
The INSIGHT MM study will be the largest pharmaceutical company-sponsored study of its kind in multiple myeloma, with the goal to enroll up to 4,200 patients 18 years or older with newly diagnosed or relapsed/refractory multiple myeloma globally.
The INSIGHT MM study is led by a steering committee of myeloma experts.
The purpose of this observational study is to collect information regarding your medical history and how your condition is managed during your routine treatment.
The study may provide a better understanding of current multiple myeloma patients globally, and ways in which they are cared for after they are diagnosed.
The study is split into 2 periods:
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.